NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.88 mln
Earnings Date07/30/2026
EPS
3,226
Exceptional
P / E
0.00
Anomalous
Piotroski F-Score
2
/ 9
Weak
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.02
Debt-free
ROE
-111
Deeply negative
Business Description
Purple Biotech Ltd. is an Israel-based clinical-stage biopharmaceutical company working to help cancer patients whose tumors resist treatment or evade the immune system. The company is advancing several experimental therapies, including two drugs currently in Phase 2 trials targeting pancreatic cancer, head and neck cancer, and colorectal cancer, as well as an early-stage program aimed at stimulating the immune system to attack tumors. Purple Biotech works alongside Bristol Myers Squibb to test one of its key treatments in combination with a widely used immunotherapy drug.
